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using a prevalence-based cost-of-illness approach. METHODS:
A retrospective cohort observational study was conducted. The
direct medical costs incurred at the public hospital were collected
from a hospital electronic database. The other costs were esti-
mated using a standard Chinese questionnaire. The ﬁgures
obtained were extrapolated to estimate the total burden for the
whole T2DM population in Hong Kong. The study was con-
ducted from the perspective of a public hospital. RESULTS: Two
hundred and four patients with T2DM were randomly selected
to join this study and 147 were subsequently enrolled. Annual
total direct medical cost per patient was US$1492 in which the
government was shouldering 90.6%, while the patients only paid
for the remaining 9.4%. Among these, specialist outpatient clinic
visit costs and inpatient costs were the major cost drivers, which
contributed up to 39.6% and 43.0% of the overall cost, respec-
tively. The direct medical cost jumped dramatically, by 1.3 
times, if the patient had complications. The total government
direct medical cost for those without complication was
US$1254/patient/year, which would jump to US$1692 for
patients developing both microvascular and macrovascular com-
plications. T2DM was found to have signiﬁcant impact to the
local health care budget. It contributed to about 5.0% of the
total Hong Kong health care expenditure. CONCLUSIONS:
This study conﬁrmed T2DM and its complications pose a sig-
niﬁcant burden on the health care budget of Hong Kong. Slowing
the progression of the disease to the more advanced and costly
states should be cost saving.
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OBJECTIVE: To estimate the French hospital extra costs of car-
diovascular events (CVE) occurring in diabetic and non diabetic
patients. METHODS: Hospital stays were extracted from the
2003 national Diagnosis Related Group (DRG) including the
whole French stays (around 18 million records). Stays were
selected on the ICD-10 and/or procedures codes related to the
following events: stroke, myocardial infarction, unstable angina,
and coronary revascularisation. Diabetic patients were picked
out using secondary diagnosis related to diabetes mellitus (type
I and II). The level of resource consumption and average length
of stay were analyzed in both diabetic and non diabetic groups.
For the economic analysis, an adjustment method based on
national DRG costs (public and private hospitals) was used to
take into account extra length of stay of diabetic patients com-
pared with average DRG length of stay. RESULTS: Average
length of stay of diabetics was signiﬁcantly longer than non dia-
betics (stroke: 2.45 days, myocardial infarction: +1.48 days,
unstable angina: +1.25 days, revascularisation: 2.82 days; p <
0.001 for each). The mean number of medical procedures
recorded by stay was higher in the diabetic group (stroke: +0.51;
myocardial infarction: +0.80, unstable angina: +0.92, revascu-
larisation: +1.91; p < 0.001 for each) and diabetic patients had
more Intensive Care Unit transfer for myocardial infarction and
unstable angina (odd ratio diabetic versus non diabetic: 1.7 and
1.3; p < 0.001). Adjusted hospitalization costs of events for dia-
betic patients were the following: stroke (non fatal event): €5703,
myocardial infarction (non fatal event): €4721, unstable angina:
€4147, coronary revascularisation: €11,679. The overcosts of
diabetic patients for these events compared with average DRG
cost were respectively +23.9%, +10.4%, +6.1% and +9.1%.
CONCLUSION: Diabetic patients with CVE required higher
medical consumptions than non diabetic during hospital man-
agement. Extra costs associated with diabetes were estimated
and can be used in cost-effectiveness studies.
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OBJECTIVES: Cost study of diabetes therapy was conducted at
national level in 1997 but the introduction of health insurance
system and a lot of new medicines changed treatment patterns
as well the cost of therapy. The goal of this study is to analyse
the cost of diabetes therapy from the National Health Insurance
Fund (NHIF) point of view and to compare prescribing practice
with the previous study. METHODS: Information by the NHIF
electronic data base was collected at national level and repre-
sentative sample of 3410 and 2440 prescriptions for type-1 and
type-2 diabetic patients was analyzed. The observed patients
were also systematized for the available complications and their
treatment cost was calculated on the basis of NHIF tariffs. Man-
ufacturers’ information for the insulin market was collected and
compared with the prescribing information. RESULTS: The
number of diabetic patients increased since 1997 from 150,000
to 225,000 and patients on insulin therapy account for 35%.
The cost of the ambulatory treatment with peroral antidiabetics
account for €800,000 while expenditures for insulin are €32
million. The metformin was prescribed in 43% and glibenclamid
in 25% of prescriptions. It was revealed substantial growth in
the total insulin market from 610MU in 1997 to 969MU sold
in 2004 with prevailing prescribing of insulin mixtures in 59%.
Micro and macro vascular complications prevail in 97% of the
patients and account for 59% of expenditures paid for hospi-
talization and 20% of ambulatory expenditures. Expenditures
for insulin account for 18% of the cost of diabetes treatment
while per oral antidiabetics for less than 8%. CONCLUSION:
The cost of insulin treatment of one patient is close to cost
reported by similar European studies but Bulgaria delay with the
introduction of insulin analogues and it could affect the future
complications therapy.
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OBJECTIVES: Intensive insulin treatment is associated with an
increased risk of hypoglycemic events in type-1 diabetes. A recent
26-week randomized clinical trial demonstrated that basal/bolus
treatment of type-1 diabetic patients with insulin detemir +
insulin aspart (IDet/IAsp), compared to insulin glargine + insulin
aspart (IGlar/IAsp), led to a 72% lower risk of major hypo-
glycemic events (p < 0.05). METHODS: A validated model was
used to project long-term complications, quality-adjusted life
expectancy, long-term direct and indirect costs, and incremental
cost-utility ratios (ICURs) for IDet/IAsp versus IGlar/IAsp in
Austria and Germany. Markov modeling was used to describe
the incidence and progression of complications (cardiovascular
disease, neuropathy, renal and eye disease). Probabilities of com-
